ArticlePCN reports : psychiatry and clinical neurosciences2026
The importance of longitudinal evaluation using DAT-SPECT in organophosphate-induced toxic parkinsonism.
Article in PCN reports : psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The importance of longitudinal evaluation using DAT-SPECT in organophosphate-induced toxic parkinsonism.PCN reports : psychiatry and clinical neurosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinicians encounter considerable challenges in the diagnosis and treatment of organophosphate-induced toxic parkinsonism following acute poisoning. Here, we report the importance of longitudinal evaluation of a patient with organophosphate-induced toxic parkinsonism using dopamine transporter single-photon emission computed tomography (DAT-SPECT). This case may provide crucial insights into the pathophysiology of the syndrome and inform therapeutic decision-making. Case Presentation: We report a case of organophosphate-induced toxic parkinsonism with persistent parkinsonian symptoms evaluated longitudinally using DAT-SPECT. A 68-year-old woman with a history of bipolar disorder was found collapsed at home on Day 0 with impaired consciousness, miosis, hypersalivation, and bradycardia. Organophosphate poisoning was diagnosed based on markedly reduced cholinesterase levels and the presence of an organophosphate pesticide in a shed at her home. Parkinsonian symptoms gradually emerged from Day 18, including hypophonia and a gait disturbance. On Day 60, DAT-SPECT showed reduced radiotracer uptake in the bilateral striatum, more pronounced on the right. After toxic parkinsonism was diagnosed, l-dopa was titrated up to 600 mg/day without clinical benefit and discontinued due to adverse effects. Treatment with amantadine and trihexyphenidyl was then initiated, resulting in partial symptomatic improvement, although symptoms persisted. Despite clinical improvement, follow-up DAT-SPECT on Day 131 showed a further reduction in striatal tracer uptake, whereas quantitative improvement was observed on Day 200. Conclusion: Parkinsonism is an uncommon sequela of organophosphate poisoning and may be accompanied by abnormal DAT-SPECT findings. Moreover, amantadine and trihexyphenidyl may represent effective therapeutic options for this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.